These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17159771)

  • 21. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.
    Stiborova M; Rupertova M; Schmeiser HH; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2006 Jul; 150(1):13-23. PubMed ID: 16936898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
    Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
    Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
    Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
    Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.
    Stiborova M; Cerna V; Moserova M; Arlt VM; Frei E
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():43-54. PubMed ID: 24362092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
    Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
    Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
    Stiborová M; Rupertová M; Frei E
    Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidation of an antitumor drug ellipticine by peroxidases.
    Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
    Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy.
    Stiborová M; Hájek M; Frei E; Schmeiser HH
    Gen Physiol Biophys; 2001 Dec; 20(4):375-92. PubMed ID: 11989648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
    Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
    Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450.
    Peng HM; Raner GM; Vaz AD; Coon MJ
    Arch Biochem Biophys; 1995 Apr; 318(2):333-9. PubMed ID: 7733661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
    Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
    Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
    Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
    Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
    Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on covalent binding of (-)trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene metabolites to cytochromes P-450 LM2 and LM4 and NADPH-cytochrome P-450 reductase.
    Deutsch J; Vatsis KP; Leutz JC; Coon MJ; Gelboin HV
    Xenobiotica; 1989 Dec; 19(12):1421-35. PubMed ID: 2515665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Redox cycling in the metabolism of the environmental pollutant and suspected human carcinogen o-anisidine by rat and rabbit hepatic microsomes.
    Naiman K; Dracínská H; Martínková M; Sulc M; Dracínský M; Kejíková L; Hodek P; Hudecek J; Liberda J; Schmeiser HH; Frei E; Stiborová M
    Chem Res Toxicol; 2008 Aug; 21(8):1610-21. PubMed ID: 18624415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect.
    Celik H; Arinç E
    J Pharm Pharm Sci; 2008; 11(4):68-82. PubMed ID: 19183515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz.
    Clement B; Demesmaeker M; Linne S
    Chem Res Toxicol; 1996 Jun; 9(4):682-8. PubMed ID: 8831810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and partial characterization of the adduct formed by 13-hydroxyellipticine with deoxyguanosine in DNA.
    Moserova M; Kotrbova V; Rupertova M; Naiman K; Hudecek J; Hodek P; Frei E; Stiborova M
    Neuro Endocrinol Lett; 2008 Oct; 29(5):728-32. PubMed ID: 18987592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzymes involved in the metabolism of the carcinogen 2-nitroanisole: evidence for its oxidative detoxication by human cytochromes P450.
    Miksanová M; Sulc M; Rýdlová H; Schmeiser HH; Frei E; Stiborová M
    Chem Res Toxicol; 2004 May; 17(5):663-71. PubMed ID: 15144223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.